How the approval-probability curve prices biotech risk

"Why is a drug with a 13% chance of reaching market worth more than a drug with an 87% chance?"

That is the question underneath every biotech price, and it is almost never asked out loud. Analysts quote probability-of-approval numbers, known as PoA, as if they were labels on a jar. Investors nod and move on. Nobody checks which shelf the number came from.

Approval odds are not predictions. They are base rates: historical frequencies of a defined event in a defined population. Used properly, they are the closest thing biotech has to a level playing field. Used loosely, they are decoration on a stock pitch.

The base rates that set valuations

Every biotech valuation starts at the same table. It is the historical frequency of approval at each step of the regulatory ladder, and it barely moves from year to year.

About one drug in ten enters Phase 1 and survives to approval. Reach a clean Phase 2 readout and the base roughly triples. Get through Phase 3, and the odds cross the halfway line. A company with a complete application and no prior rejection sits at an 85% base rate. Priority review lifts that to 90%. An orphan designation pushes it to 93%.

The useful part is watching the deviations, not the averages. A base rate is a prior. Every dollar of valuation that depends on approval rests on the gap between that prior and the specific facts of the trial: the endpoint, the sample size, the comparator arm, the history of the mechanism class.

"Works in mice" is Phase 2 talk. Everything after that gets priced in dollars, and the pricing is merciless.

A PDUFA date becomes a price

The Prescription Drug User Fee Act gives the agency a target date to decide on a finished application. On that date, the agency approves the drug, issues a Complete Response Letter, or asks for more. The market does not wait to find out which one.

BiopharmaWatch's live calendar prices exactly this: a first-in-class tau PET diagnostic for Alzheimer's, Lantheus' MK-6240, trades a probability of approval of 87.5% ahead of its August 13 decision. Capricor's deramiocel comes with a prior Complete Response Letter on its file, and the calendar marks its implied swing at plus or minus 67% across its August 22 decision date.

Missing a catalyst date can mean missing a 40-200% move in a single session, in either direction. The statistics do not cause the move. The calendar does.

The catalyst-tracking industry is careful to call its probability-of-approval scores historical base rates, not predictions. BiopharmaWatch and its peers derive them from agency data, and they license no claim about this drug, in this indication, with this data package.

Where the odds break

Base rates fail in four recognizable places, and each one shows up in a market price long before it shows up in a headline.

First, a prior rejection. A Complete Response Letter sits on the file as a scar, and the base rate for the refiled application drops by roughly 28 points against a clean counterpart. Deramiocel is the live example of that discount being priced.

Second, a thin evidence package behind an early designation. Accelerated approval and Fast Track status shorten the calendar but do not change the biology. The agency has become less willing to let urgency do the work of data.

Third, the cohort effect. The commercial expectations for the agency's Q1 2026 approval cohort are low: forecast 2030 sales of about $4.7 billion for the ten novel drugs approved, against more than $9 billion for the Q1 2025 cohort. The same probability of approval, a materially thinner commercial story.

Fourth, the class history. Every mechanism carries its own graveyard. Incretins cleaned it up. CRISPR is still walking through its Phase 3 years. The market prices the class record, not the press release.

The approval lottery, compared

Read that table as the market does: differences of a few points at the top of the ladder are commercial voltages. A standard NDA at 85% and an orphan application at 93% are eight points apart on paper and a different risk class in practice.

What the 2026 wave priced

The approval flow of early 2026 was a demonstration of the base rates working as advertised. Denali's AVLAYAH cleared a 93% obscured prior. Lilly's oral GLP-1, Foundayo, converted a 90% base into an approval. Travere's Filspari, Geron's Rytelo, Arvinas' vepdegestrant: all turned high-probability filings into wins in the first half of the year.

Then came the harder August block. Bristol Myers' iberdomide faces its August 17 decision in relapsed multiple myeloma. Gilead's single-tablet bictegravir/lenacapavir HIV regimen lands on August 27. ITM's 177 Lu-edotreotide follows a day later. Moderna's mRNA flu vaccine already cleared its August 5 verdict with a 26.6% efficacy edge, as we wrote earlier this month.

These are the moments where the probability theory meets an actual calendar, and the market re-prices a company in hours.

Running the exercise on a single name

The framework only earns its keep when you apply it to one company, cheaply and for real. Pick a name with a decision on the calendar and go through the file in five minutes.

Start with the application type. A standard NDA opens at 85%, priority review at 90%, an orphan designation at 93%. Write the number down. It is your statistical floor, the population frequency before a single trial detail is added.

Then adjust for the scars. A prior Complete Response Letter on the file knocks about 28 points off the base, and the discount shows up in the stock long before the decision date. Read the prior letter if you can find it. The agency almost always says, in writing, what would change its mind.

Then look at the cohort, not the drug. A drug in a crowded class is being priced against its neighbors, not against the base rate. The Q1 2026 cohort proves the point: ten approvals, but a 2030 sales forecast of $4.7 billion against more than $9 billion a year earlier. Same odds of approval, a different commercial ladder.

Finally, anchor to the calendar. A company ahead of a binary date is trading the date, everything else is noise for the week. The discipline is to decide, before the date, what you would pay at 0% and at 100% probability, and to make the gap your own edge instead of the market's.

That is the whole exercise. Five minutes, no terminal, no tip sheet. The base rate gives you the floor, the file gives you the adjustment, and the calendar gives you the moment.

Probability as a framework, not a ticket

The quiet shift is the professionalization of the approximation. Catalyst calendars now publish probability-of-approval scores as a matter of course, normalized against the same agency historical tables. That is good hygiene. It is also a discipline the retail habit of reading a trial headline as a verdict will have to learn the hard way.

Approval odds tell you the frequency of an event in a population. They do not tell you whether this drug is the event. The gap between the two is where the diligence lives, and the base rates are only the opening negotiation.

The market is efficient at pricing the known. It is the refiled application, the thin cohort, and the class graveyard where the edges sit.

The next time an analyst quotes an approval probability, ask two questions. What is the base rate for this application type? And what does this specific trial file add or subtract from it? A man who can answer both has a framework. A man who cannot has a number.